Seven life sciences companies will present live at the Life Sciences Virtual Investor Forum on Thursday, September 17, 2026, giving investors direct access to management teams through 30-minute sessions and audience Q&A. The online event, hosted by Virtual Investor Conferences and marketed by B2i Digital, Inc., spans oncology, fibrosis, drug delivery, antibiotics, cannabinoid therapeutics, and respiratory imaging. The forum matters because it provides a real-time window into a diverse set of early- and clinical-stage programs at a moment when investors are weighing scientific innovation against regulatory and commercial risks.
The lineup includes Sona Nanotech Inc., which is developing a photothermal cancer therapy built on gold nanorods; Raphael Pharmaceutical, which is advancing cannabinoid-based formulations for rheumatoid arthritis, chronic lung inflammation, and autoimmune disease; and Amplia Therapeutics Ltd., which has a pipeline of Focal Adhesion Kinase inhibitors for cancer and fibrosis. Adaptin Bio, Inc. will present precision drug delivery technologies aimed at target tissues, including behind the blood-brain barrier, while Acurx Pharmaceuticals, Inc. is developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens. CytoDyn Inc. is studying a humanized monoclonal antibody in solid-tumor oncology, and 4DMedical Ltd. offers FDA-cleared four-dimensional respiratory imaging.
The forum’s format allows investors to hear directly from executives and ask impromptu questions, a feature that B2i Digital CEO David Shapiro highlighted. “Reading company filings is a great cure for insomnia, but if you want to stay awake and hear it directly from management, these conferences are the best way to get a real feel for the company,” Shapiro said. “My favorite part is the Q&A and hearing how they handle the impromptu questions that are really on your mind.” That direct engagement can be especially valuable for smaller companies that may not have broad analyst coverage.
Event details and presenting company profiles are available at https://b2idigital.com/sept-17-life-sciences-virtual-investor-forum. Investors can register at https://www.virtualinvestorconferences.com/wcc/eh/4814904/category/150412/september-17th-life-sciences-virtual-investor-forum?utm_source=b2i&utm_medium=marketing&utm_campaign=0917SeptLifeScienceVIC. Replays will be available on the B2i Digital and OTC Markets YouTube channels. Virtual Investor Conferences, an OTC Markets Group Inc. property, regularly features public companies from exchanges worldwide, including NYSE, Nasdaq, TSX, TSXV, CSE, ASX, LSE, and the OTC Markets.
B2i Digital is the Official Marketing Partner for the forum, leveraging a media network that spans more than 800 news, broadcast, and trade outlets with a combined monthly audience exceeding 330 million, plus over 1.7 million followers and 70,000 opt-in email subscribers. The event is scheduled to begin at 11:00 AM ET with Sona Nanotech, followed by Raphael Pharmaceutical at 11:30 AM ET, Amplia Therapeutics at 2:00 PM ET, Adaptin Bio at 2:30 PM ET, Acurx Pharmaceuticals at 3:00 PM ET, CytoDyn at 3:30 PM ET, and 4DMedical at 4:00 PM ET. The presenting companies are subject to change. More information about B2i Digital’s featured companies, experts, and conferences is available at https://b2idigital.com.
